Healthcare Supply Chain Management

𝗪𝗵𝘆 𝗮 𝗦𝗲𝗰𝘂𝗿𝗲 𝗮𝗻𝗱 𝗖𝗼𝗻𝘀𝗶𝘀𝘁𝗲𝗻𝘁 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗮𝗻𝗻𝗮𝗯𝗶𝘀 𝗦𝘂𝗽𝗽𝗹𝘆 𝗖𝗵𝗮𝗶𝗻 𝗜𝘀 𝗩𝗶𝘁𝗮𝗹 𝗳𝗼𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝗮𝗳𝗲𝘁𝘆 In medical cannabis, consistency is not a luxury, it is a clinical requirement. When a patient relies on a specific product to control pain, anxiety, epilepsy, or any other condition, the stability of that product is fundamental to their treatment. A secure supply chain underpins this stability, yet it is often the most overlooked part of the industry. The most successful pharmaceutical systems in the world rely on predictable, validated, & repeatable supply chains. Medical cannabis should be no different. If the raw material changes from one batch to the next, the patient experience changes with it. When there are delays, stock-outs, or last-minute substitutions, the impact is felt directly by the people who rely on these medicines every day. A secure supply chain ensures several critical outcomes. It makes consistent cannabinoid & terpene profiles across every batch, allowing clinicians to prescribe confidently & patients to trust the product they receive. It reduces the risk of contamination, mislabelling, or degradation during transport & storage. It also ensures that each step of the process, from cultivation to processing to packaging, is carried out under audited & compliant conditions. The consequences of an insecure supply chain are significant. Patients can experience sudden changes in efficacy, unexpected side effects, or a complete loss of therapeutic benefit. Clinics face reputational harm, pharmacists struggle with unpredictable stock, & regulators lose confidence in the system. Ultimately, when supply chain integrity fails, patient safety is compromised. A strong supply chain is built on three pillars. The first is cultivation partners who follow GACP & produce stable, validated genetics. The second is processing facilities operating under EU GMP, delivering pharmaceutical-grade consistency. The third is a logistics pathway that protects product integrity & ensures uninterrupted supply. The industry must recognise that competition based solely on price is short-sighted. Medical cannabis must be treated with the same seriousness as any other medicine, where quality, consistency, & reliability define the value. Companies that prioritise secure supply chains earn trust, build long-term partnerships, & ultimately deliver better outcomes for patients. If we want medical cannabis to stand shoulder to shoulder with established therapies, then the industry must commit to stable, secure, & compliant supply chains. This is not only good practice, it is an ethical obligation to the patients who depend on us. If you would like support strengthening your supply chain, auditing your partners, or validating your products from seed to sale, I can assist with a full review of your operations and compliance readiness. Note: Picture is not real and made for illustration purposes only.

We can’t scale CAR-T with the current centralized manufacturing mindset. ZS Associates conducted a deep-dive on decentralized manufacturing for autologous CAR-T therapies, and it confirms what many have suspected for years: Centralized production doesn’t match the biology or the economics. Here are the big observations from the analysis: 1. Decentralization is possible - and it’s necessary. - Current costs of a single CAR-T batch manufactured centrally? $250K–$380K. - Much of that is upfront fixed cost (CAPEX, IT, asset maintenance). - Decentralized platforms should shift that model toward lower-risk OPEX, allowing for faster, leaner delivery near the bedside. 2. Cold chain logistics are killing your lead times. - Long-distance transport introduces bottlenecks, handoffs, and storage risk. - Local manufacturing means you could skip the freezer altogether --(Galapagos is doing this already) - And patients get treated faster. 3. >25% failure rates are not affordable. - Decentralized + automated systems allow faster retries when batches fail. - When time = survival, flexibility matters. - High OOS rates increase COGS that are already too high and put patients at risk 4. CGT economics only work if the process scales. - ZS estimates cost savings of up to 75% per batch when using automated, decentralized models at scale. - That’s how we can turn personalized cell therapy from niche to viable. - Even if the cost manufacturing was the same as centralized, reducing logistics costs/complexity and shorter vein-to-vein times make decentralized worth exploring 5. Regulatory alignment is the next step. - The paper calls for smarter master files, better digital/technology infrastructure, and a shift in how regulators define the “process = product” equation. - The tech is ready— we need policy to catch up.  The UK has already planted the decentralized flag, we need US and EU to follow. TLDR: - Autologous CAR-T is struggling to scale with centralized manufacturing - A decentralized, automated, modular model is a potential path forward - Cold chain and complex logistics isn’t helping enable access - The cost model is fixable with automation and flexible manufacturing models - The real bottleneck is mindset, not tech There is a new blueprint emerging for commercial viability in CGT. Let’s build. #celltherapy #cellandgenetherapy #biotechnology #manufacturingbrighterfuturestogether

𝗪𝗵𝗲𝗻 𝗮 $𝟭 𝗢-𝗥𝗶𝗻𝗴 𝗕𝗲𝗰𝗼𝗺𝗲𝘀 𝗮 𝗠𝗶𝗹𝗹𝗶𝗼𝗻-𝗗𝗼𝗹𝗹𝗮𝗿 𝗣𝗿𝗼𝗯𝗹𝗲𝗺 During the COVID-19 pandemic, I watched a gene therapy company halt a validation campaign mid-stream. Not because of the virus itself. Because they couldn't get critical raw materials. The regulatory filing that should have happened in 2020 didn't happen until years later. That experience has stuck with me. I created this supply chain map to visualize where CGT raw materials come from. The pattern is striking: one company, Thermo Fisher Scientific, dominates across nearly every category. Here's what worries me about this concentration. In 2020, about one-third of cell therapy manufacturers experienced shutdowns or major delays. Raw materials got diverted to COVID vaccine development. Viral vector manufacturing became a zero-sum game between vaccine makers and gene therapy developers fighting for the same capacity. Companies like Bluebird Bio saw their regulatory timelines pushed back by years. The disruptions weren't always high-tech. Sometimes it was plastic components. Sometimes it was FFKM o-rings for bioreactor seals. One manufacturer couldn't get specific tubes needed for apheresis. These components cost dollars, not thousands. But without them, validated processes stop cold. That's the paradox of CGT supply chains. Over 95% of critical materials are sole-sourced or single-sourced from one provider, often manufactured in a single location. You can't just substitute a different o-ring or a different media formulation. Your process validation locked you into specific suppliers for specific components. When one company touches every aspect of that supply web, your risk concentrates. Their operational issues become your operational issues. Their strategic priorities become constraints on your development timeline. Their capacity becomes your ceiling. The CGT market is scaling fast, from $6.24B in 2024 toward $73B by 2034. As we grow, this structural vulnerability doesn't shrink. It amplifies. We learned during COVID that supply chain resilience matters more than supply chain efficiency. Just-in-time inventory works beautifully until it doesn't. Single-source relationships work great until that source has a problem. The industry needs to act: Qualify secondary suppliers before crises force the issue Build consortia to support emerging competitors Consider vertical integration for truly strategic materials Make supply chain resilience a regulatory consideration Gene therapies are potentially curative. Patients can't wait years for supply chain issues to resolve. We need to build redundancy into this system before the next disruption hits. Have you experienced supply chain bottlenecks that delayed your programs? What strategies have worked for you? #GeneTherapy #CellTherapy #Biomanufacturing #SupplyChain #COVID19Lessons

🔍 Opinion: Cell & gene therapies don’t fail in the clinic — they fail in the factory. The FDA’s new Advanced Manufacturing Technologies (AMT) designation could finally help CGT scale, support post-approval pivots, and make treatments reliably accessible to patients who need them. 🧬 Why does CGT struggle to scale? Regulatory approval is not the finish line — it’s where the hardest challenge begins. Most CGT companies discover too late that manufacturing processes that worked during development collapse under commercial pressure: 🔨Manual, labour-intensive workflows 📃Paper-based QC ⚙️Limited automation 🔁Site-to-site variability 🐌Slow release cycles ⏳Capacity constraints that turn waitlists into bottlenecks It’s why we’ve seen multiple high-profile commercial failures, despite strong science. 🏥 FDA steps in: Advanced Manufacturing Technologies (AMT) The FDA’s AMT designation — finalised late last year — gives companies a structured path to: ⬆️Upgrade manufacturing after approval 🕐Align early with FDA reviewers 🔧Reduce friction in comparability packages ⚖️Deploy platform technologies across multiple sites ✅Improve consistency, inspection readiness and supply continuity Platforms from companies like Cellares, Cellino and Ori Biotech are among the first to secure AMT status — potentially a lifeline for biotechs trying to modernise manufacturing while keeping approved products on the market. ⚠️ Why this matters for patients Failing to scale doesn’t just affect revenue — it affects access. We’ve already seen 8 out of 28 EMA-approved CGTs withdrawn for commercial reasons. In the US, we watched bluebird bio’s commercial struggles, and more recently, Takeda and others hit pause or step back from their CGT pipelines due to unclear scalability, unsustainable COGS and operational complexity. If the science works but the manufacturing doesn’t, patients lose out. 🚀 The takeaway CGT needs advanced, automated, and scalable manufacturing platforms if it’s ever going to reach real-world impact. The FDA’s AMT designation may not solve everything, but it signals a clear truth: better manufacturing isn’t optional — it’s the future of cell & gene therapy. 🔧🧬 For the industry, this is a wake-up call. 💙 For patients, it’s hope that innovation won’t end at approval. #CGT #FDA #Pharma Symptome

𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗼𝗻’𝘁 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗳𝗿𝗼𝗺 𝗮 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗵𝗲𝘆 𝗰𝗮𝗻’𝘁 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆 𝗮𝗰𝗰𝗲𝘀𝘀. This Bloomberg article is a good reminder that getting a radioligand therapy to a patient is not simply a drug development challenge. It is an ecosystem execution challenge. The clinical results are remarkable. Investment is accelerating. But none of it reaches a patient without an operational chain that has almost no room for error. Every dose depends on: • Isotope and starting material sourcing, often spanning multiple countries • Reactor or accelerator access for irradiation • Isotope purification • Radiopharmaceutical manufacturing • Quality control and batch release • Time-sensitive transport across borders and customs • Radiopharmacy, hospital capacity, and treatment-site readiness • Trained staff and radiation safety protocols • Waste management and regulatory compliance • Patient scheduling tied to a decay clock that does not wait The ecosystem is also becoming increasingly sensitive to 𝗴𝗲𝗼𝗽𝗼𝗹𝗶𝘁𝗶𝗰𝗮𝗹 𝗲𝘃𝗲𝗻𝘁𝘀, 𝗮𝗴𝗶𝗻𝗴 𝗿𝗲𝗮𝗰𝘁𝗼𝗿 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲, 𝘁𝗿𝗮𝗻𝘀𝗽𝗼𝗿𝘁𝗮𝘁𝗶𝗼𝗻 𝗱𝗶𝘀𝗿𝘂𝗽𝘁𝗶𝗼𝗻𝘀, 𝗮𝗻𝗱 𝗲𝘅𝗽𝗼𝗿𝘁 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝘀, 𝗺𝗮𝗸𝗶𝗻𝗴 𝗿𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝗰𝗲 𝗷𝘂𝘀𝘁 𝗮𝘀 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗮𝘀 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆. Lutetium-177 has a 6.6-day half-life. Actinium-225, 9.9 days. Some isotopes used in nuclear medicine decay within hours. A delay at any point in the chain, whether in sourcing, irradiation, manufacturing, transport, or scheduling, is not simply a logistics issue. 𝗜𝘁 𝗰𝗮𝗻 𝗺𝗲𝗮𝗻 𝗮 𝗺𝗶𝘀𝘀𝗲𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗳𝗼𝗿 𝗮 𝗽𝗮𝘁𝗶𝗲𝗻𝘁. This is the part of the radiopharmaceutical story that often receives less attention than the science, yet it will largely determine 𝗵𝗼𝘄 𝗺𝘂𝗰𝗵 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝗲𝗱 $𝟯𝟬 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗺𝗮𝗿𝗸𝗲𝘁 𝘂𝗹𝘁𝗶𝗺𝗮𝘁𝗲𝗹𝘆 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗲𝘀 𝗶𝗻𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗰𝗰𝗲𝘀𝘀. 𝗧𝗵𝗲 𝗻𝗲𝘅𝘁 𝗽𝗵𝗮𝘀𝗲 𝗼𝗳 𝗴𝗿𝗼𝘄𝘁𝗵 𝗶𝗻 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗱𝗿𝗶𝘃𝗲𝗻 𝗻𝗼𝘁 𝗼𝗻𝗹𝘆 𝗯𝘆 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻, 𝗯𝘂𝘁 𝗮𝗹𝘀𝗼 𝗯𝘆 𝗼𝘂𝗿 𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗯𝘂𝗶𝗹𝗱 𝗮 𝗿𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝘁, 𝗰𝗼𝗼𝗿𝗱𝗶𝗻𝗮𝘁𝗲𝗱 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝗰𝗮𝗽𝗮𝗯𝗹𝗲 𝗼𝗳 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗶𝗻𝗴 𝘁𝗵𝗲𝘀𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆 𝗮𝗻𝗱 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲. 🔗 to article: https://lnkd.in/gDfGgxyz